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Toxicity attributed to sertraline has been demonstrated recently in different cell types and also in some organisms. We investigated
the effect of sertraline on planarians, which are considered suitable for investigations in neurotoxicology and currently are widely
used as an animal model in neuropharmacological studies. Planarians treated with 10𝜇M sertraline showed a rapid reduction
in their spontaneous movement until they became completely motionless and then showed a series of asynchronous paroxysms
(seizures) followed by progressive tissue damage, beginning 48 h after the sertraline treatment, and died approximately 72 h later.
Our data showed that sertraline does not cause planarian death within the range of therapeutic concentrations; however, behavioral
alterations were observed with concentrations that can be considered compatible with therapeutic ones, such as a significant
reduction in planarian locomotory activity at 0.4 𝜇M. Treatment with 4 𝜇M sertraline had a significant effect, reducing planarian
locomotory activity and increasing the number of asynchronous paroxysms; both effects were significantly maintained even 24 h
after the sertraline was withdrawn. These behavioral changes observed at low micromolar concentrations suggest that sertraline
might have residual biological consequences for planarians, even after it is withdrawn.
1. Introduction
Sertraline (Zoloft) is a selective serotonin reuptake inhibitor
that is widely prescribed as an antidepressant [1] and is
also used for the treatment of panic, obsessive-compulsive,
and posttraumatic stress disorders [2]. Beyond its classic
mechanism of action, extensive evidence suggests that ser-
traline possesses other biological activities that appear to be
unrelated to its inhibition of serotonin reuptake [3]. Among
these additional biological effects, sertraline was recently
reported to inhibit Na+ and K+ voltage-dependent channels
[3–9] as well as to reduce glutamate uptake [10]. Regarding
an effect of sertraline on Ca2+ channels, it was recently
reported that it can induce a rise in the levels of cytosolic
free Ca2+ partly through these channels and also through
endoplasmic reticulum release in cancer cells [11, 12], where
it also induced apoptosis [12, 13]. Although sertraline is
considered a safe drug, several reports have associated it with
toxic effects on the liver [14–16] and hepatic cells [2, 13, 17].
Recently, cardiac toxicity has been related to sertraline, even
in therapeutic doses [18, 19], and its use during pregnancy
was associated with an increased risk of major malforma-
tions [20] and compromise of embryonic bone development
[21].
Recently, planarians have been proposed as an alternative
model for investigations in neurotoxicology [22, 23], showing
sensitivity to chemicals comparable to other animal models
used in toxicological studies, such as zebrafish larvae and
nematodes [22]. Planarians possess an aggregate of neurons
in the head that are very similar to those of vertebrates.
The major shared similarities include the multipolar shape,
dendritic spines with synaptic boutons, a single axon, and
relatively low spontaneously generated electrical activity
([24]; for review see [25]). Planarians also possess several
neurotransmitter-receptor systems and are widely used as
an animal model in neuropharmacological studies [25].
For instance, they present a serotonergic system that share
some similarities with those found in vertebrates [25] and
where serotonergic drugs showed effect on both spontaneous
locomotor velocity and behavior [26].
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In view of the recent reports of sertraline toxicity, we
decided to investigate this issue employing a well-established
animalmodel that is used in pharmacological and toxicologi-
cal studies.We investigated if sertraline could affect planarian
behavior and cause toxicity in these animals.
2. Methods
2.1. Drug andMaterials. Sertraline (Sigma-Aldrich, St. Louis,
Missouri, USA) was dissolved in sterile water and stored
as stock solutions. On the day of the experiment, stock
solutions were diluted to desired concentrations in artificial
pond water (APW) (deionized water, 6mMNaCl, 0.1mM
NaHCO
3
, and 0.6mM CaCl
2
). An HDL HM-Pro 480 video
camera (Amazonas, Brazil) with a manual iris varifocal lens
(2.8–12.0mm, sensitivity 0.5 lux), Greatek GTK-DVR04A,
H.264, NTSC digital video recorder (São Paulo, Brazil),
square open-top plastic cube container (6 cm × 6 cm), HT-
2 hand tally counter (Taiwan, ROC), and electronic timer
(VWR International, Radnor, PA, USA) were used in these
studies. Focal length was maintained at 10 cm.
2.2. Subjects. Planarians (Dugesia tigrina) obtained from
the Laboratory of Platyhelminthes (Department of Zoology,
UFRGS, Brazil) were stored in Tupperware containers at 21∘C
in the dark. Animals were fed organic beef liver once a week,
and the water (APW) in their container was changed twice a
week.
2.3. Procedures. The protocol used is standard for behav-
ioral experiments and had a duration of 72 h. During the
experimental period, each planarian was maintained at room
temperature (21∘C) under a 12 h dark-light cycle, in a clear
plastic square dish (6 cm × 6 cm) filled with 9mL APW.
Planarians 1.0–1.5 cm in length, chosen randomly, were fed
24 h before the experiment and were not fed at any time
during the experimental procedures. Each planarian was
used only once and remained in the test dish until the
conclusion of the experiment. When necessary, the medium
(APW or APW containing the drug) was replaced with a
syringe. The video record was made from the top of the
cube. Each planarian was studied individually during 72 h,
with the following standard protocol: (1) transference to the
test dish; (2) 10min for acclimation; (3) 10min of recording
(considered as control); (4) replacement of medium with
sertraline; (5) 25min of incubation; (6) 10min of recording
(considered as sertraline 25min); (7) 24 h of incubation;
(8) 10min of recording (considered as sertraline 24 h); (9)
replacement of incubation medium with APW (5x); (10) 24 h
of incubation in APW; (11) 10min of recording (considered
as sertraline withdrawal, 24 h). Hence, the test groups were
the following: control, 25min sertraline and 24 h sertraline,
and withdrawal, 24 h. All planarians were used in each
group. In order to determine the possibility of environ-
mental and/or physical interference with the planarians
during the protocol execution, a pilot evaluation was carried
out before the sertraline was introduced. In this group,
planarians were exposed to the same conditions described
above (72 h at 21∘C, 12 h dark-light cycle, and the same
exchanges ofmedium) but weremaintained inAPWmedium
throughout.
2.4. Behavioral Studies
2.4.1. Determination of Locomotory Activity. In APW, pla-
narians exhibit normal gliding behavior. To quantify spon-
taneous planarian movement (pLMV), individual planarians
were placed in a square dish that was then placed on paper
with gridlines spaced 0.5 cm apart. pLMV was quantified as
the number of gridlines crossed or recrossed during a 10min
observation period. Normal planarian movement consists
of constant-velocity, horizontal, and forward-directed move-
ment, with periodic turns, but rarely any stops [27].
2.4.2. Determination of Seizure Events. Planarian seizure-
like activity (pSLA) is defined as asynchronous paroxysms
resulting in a sudden disruption of normal spontaneous
locomotor activity, in response to proconvulsive drugs [28,
29]. The behaviors associated with pSLA are described as
headswing (planarian stationary, tail portion fixed to ground
with head portion moving about from side to side); C-like
position (CLP) (planarian adopts a C-like shape); and screw-
like hyperkinesia (SLH) (planarian adopts a screw-like shape
with a twisting about the longitudinal axis) [30–32]. In this
study, each video recording made to quantify pLMVwas also
analyzed to identify pSLA. The asynchronous C-like, SLH,
and headswing paroxysms were quantified together as total
pSLA during 10min (the number of events counted). In this
case, overt behaviors of planarians were also photographed to
illustrate the behavioral response. The records were analyzed
by two observers, one of them blinded to the group observed.
2.5. Data Analysis and Statistical Methods. Data were ex-
pressed as mean ± SEM (𝑛 = 5). Cumulative pLMV
for each test group was expressed as a percentage of the
mean pLMV of the control group (step (3) described in
Procedures in Section 2.3). Comparisons of group means
were determined by two-way ANOVA followed by Tukey’s
multiple comparisons test (GraphPad Prism, 6.01). Statistical
significance was assumed at 𝑝 < 0.05.
3. Results
Untreated planarians exhibited normal gliding behavior (Fig-
ure 1(a)), which was quantified as spontaneous planarian
movement (pLMV). In order to investigate a potential
toxicity of sertraline, planarians were exposed to different
concentrations (0.1 to 10 𝜇M) for two weeks. During this
period, no evidence of a deleterious effect was observed with
the lower sertraline concentrations (0.1 to 4𝜇M), despite
overt alterations in the behavior of planarians maintained
at 1 and 4 𝜇M. However, when treated with the highest
concentration (10𝜇M), the pLMV was drastically reduced
around 15min later, and the planarians underwent an
intense and continuous series of seizures around 45min
after exposure. After 60min of exposure to 10 𝜇M sertraline,
the animals showed an absence of pLMV (Figure 1(b))
and repeated episodes of seizures. Continuous exposure
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Figure 1: Toxicity mediated by sertraline in planarians. In (a), a representative image of a control planarian during its gliding. (b) shows a
planarian after 1 h of exposure to 10 𝜇M sertraline, and (c) and (d) show planarians after 72 h of exposure.
for 72 h evoked partial (Figure 1(c)) or widespread dam-
age (Figure 1(d)). A deleterious effect of 10 𝜇M after an
exposure time of 72 h was detected in all planarians tested,
although the effect was more pronounced in some planari-
ans than in others. The tissue injury was progressive and
resulted in debris sloughed from the degenerating planarian
body.
The effect of sertraline on the animals’ locomotion was
studied through quantification of spontaneous planarian
movement (pLMV).The effect of different sertraline concen-
trations (0.1 to 4 𝜇M) on pLMVwas studied acutely (25min),
after 24 h of exposure, and then 24 h after the sertraline was
withdrawn. As depicted in Figure 2(a), when planarians were
exposed to sertraline for 25min, pLMV were significantly
reduced compared to the control, to 75.1 ± 3.8% (0.4 𝜇M),
59.6 ± 2.7% (1𝜇M), and 38.0 ± 10.1% (4 𝜇M), 𝑝 < 0.05, 𝑟2 =
0.999. Exposure to sertraline for 24 h significantly reduced
pLMV in respect to control to 54.7 ± 8.9% (1 𝜇M) and 19.1
± 8.4% (4 𝜇M), 𝑝 < 0.05, 𝑟2 = 0.993 (Figure 2(b)). The
withdrawal of sertraline after 24 h of treatment significantly
reduced pLMV in respect to control to 56.5 ± 9.7% (4 𝜇M)
even if 24 h after the drug has been withdrawn, 𝑝 < 0.05,
𝑟2 = 0.974 (Figure 2(c)).
Sertraline exposure reduced pLMVand also elicited overt
alterations in the planarian shape that were recognized as
asynchronous paroxysms and were photographed for records
(Figure 3). These changes in shape were not observed in
untreated planarians submitted to the same protocol, as
previously mentioned in Procedures in Section 2.3, or before
the treatment with sertraline.
The asynchronous paroxysms observed during 10min of
the recording period were counted as total planarian seizure-
like activity (pSLA) (Figure 4). The lowest sertraline concen-
trations used (0.1–1𝜇M) were not statistically different from
the control. After 25min of incubation with 4 𝜇M sertraline,
the planarians showed a significant increase in the number
of pSLA (Figure 4(a)), which remained significantly higher
after 24 h of incubation with sertraline (Figure 4(b)). Notably,
sertraline (4 𝜇M) withdrawal did not abolish the significant
increase of pSLA even after 24 h (Figure 4(c)). The effect of
4 𝜇M sertraline in increasing pSLA was significant for the
lower concentrations in all incubation times (25min, 24 h)
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Figure 2:The effect of sertraline onplanarian locomotor activity.The effect of different sertraline concentrations on the spontaneous planarian
movement (pLMV) was quantified following sequential incubations of 25min (a), 24 h (b), and 24 h after sertraline withdrawal (c). Dotted
line represents control levels. Data are expressed as mean ± SEM from 5 independent experiments (𝑛 = 5). ∗ indicates being significantly
different from the control; # indicates being significantly different from each other (𝑝 < 0.05).
and also 24 h after withdrawal (except for 1𝜇M). Additionally,
the rise in the pSLA elicited by this concentration was similar
in all three experimental conditions (Figures 4(a), 4(b), and
4(c)).
4. Discussion
The cytotoxicity of sertraline has been described in different
cell types for concentrations within a 𝜇M range, although the
degree of sensitivity of these cell types seems to differ. For
instance, considering a sertraline incubation of 24 h, cytotoxi-
city was observed from 20𝜇M in human prostate-cancer cells
(PC3) [12] as well as in osteosarcoma cells (MG63) (Lin et al.,
2013), from 25 𝜇M in a human hepatoma cell line (HepG2)
[13], from 30 𝜇M in human platelets [10], and from 37.5𝜇M
in rat primary hepatocytes [2]. Additional evidence regarding
sertraline toxicity has been reported in some organisms, such
as the parasite Leishmania donovani [33], fish, and aquatic
invertebrates [34]. In our study, sertraline (10 𝜇M) proved to
be toxic to planarians when the exposure time exceeded 48 h.
In this condition, progressively deleterious consequences
were observed, resulting in death after around 72 h. Debris
was sloughed from the animal’s body during the degenerative
process.
Our data showed that sertraline does not kill planarians
at therapeutic concentrations, which are considered to be
<1 𝜇M [35]. For instance, Saletu et al. [36] reported that a
single oral dose of 400mg sertraline administered to healthy
volunteers resulted in a plasma concentration of ∼0.74𝜇M,
while another study carried out with adults treated with
25–150mg once a day for a month found that the plasma
sertraline level was 8 nM–0.32 𝜇M [37]. However, in our
study, behavioral alterations were observed with sertraline
concentrations that can be considered compatible with the
therapeutic ones. Treatment with sertraline evoked a signifi-
cant and concentration-dependent reduction in the planarian
locomotory activity from 0.4𝜇M. This inhibitory effect was
significantly higher with 4𝜇M and was also significantly
different from the control even 24 h after the sertraline
was withdrawn. This sertraline concentration also evoked
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Figure 3: Planarian seizure-like activity evoked by sertraline. The planarian images were made after 24 h of exposure to 1𝜇M sertraline ((a)
and (b)) and 4 𝜇M sertraline ((c) and (d)). The asynchronous paroxysms C-like position ((a) and (c)) and screw-like hyperkinesia ((b) and
(d)) were observed for both sertraline concentrations.
a significant increase in the number of asynchronous parox-
ysms, with respect to the control and the other concentrations
used.The stimulatory effect on planarian seizure-like activity
remained significantly increased even 24 h after the sertraline
was withdrawn.These behavioral results are interesting since
they correspond to overt and complex effects that were
observed at low micromolar sertraline concentrations. They
also suggest that sertraline might have biological conse-
quences that persist even after it is withdrawn, which might
be explained by its capacity to accumulate in the brain tissue
[38, 39].
In rodents, serotonin receptors are related to a variety of
stereotyped behaviors such as “head shakes,” “backpedaling,”
“head-twitch,” “head-weaving,” “turning,” and “forepaw
treading” [40–42]. Considering that previous works in pla-
narians showed an effect of serotonergic drugs on both
spontaneous locomotor velocity and behavior [26], one could
suppose that sertraline effect could be related to the behav-
ioral alterations here described. In this case, bearing in mind
the sertraline’s classic mechanism of action, the inhibition of
serotonin reuptake might increase the neurotransmitter level
and consequently mediate an endogenous activation of their
receptors. However, it is important to consider that, in these
studies where behavioral effects of serotonin-addition were
observed, the concentration of the neurotransmitter added
was high, around 100–1000 𝜇M [26, 43]. Another additional
possibility to be considered might be an indirect effect of
sertraline on other neurotransmission systems, such as the
glutamatergic system.
The biological effects of sertraline seem to be more com-
plex than its traditionally described mechanism of action.
It has been recently shown that it may cause inhibition of
different types ofNa+ andK+ channels [3–8]. An inhibition of
Ca2+ channels mediated by sertraline has also been reported
in excitable cells [6], but its effect on these channels seems to
be different in other cell types [12]. Several studies [9, 11, 12]
found that it can induce an influx of Ca2+ via store-operated
Ca2+ channels in nonexcitable cells. An additional effect of
sertraline was recently described in human platelets, where it
caused a reduction in glutamate uptake [10].
Recently, several authors have attributed a wide range of
biological effects to sertraline, suggesting that many of these
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Figure 4: Quantification of planarian seizure-like activity evoked by sertraline.The effect of different sertraline concentrations on the seizure-
like activity (pSLA) was quantified following sequential incubations of 25min (a), 24 h (b), and 24 h after sertraline withdrawal (c). Data are
expressed as mean ± SEM from 5 independent experiments (𝑛 = 5). The asterisks mean being significantly different from the other groups:
∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 (ns means not significant).
effects are unrelated to its action as an inhibitor of serotonin
reuptake [3, 5, 7, 9, 11, 12]. Ohno et al. [7] suggested that
these additional biological actions may be implicated in the
therapeutic and/or adverse effects of sertraline. Ohno et al.,
[7] also showed that sertraline inhibits K+ channels, such
as the astroglial inwardly rectifying channel Kir4.1, which is
responsible for astroglial K+ buffering; and Kobayashi et al.
[5] found that it inhibits the G protein-activated inwardly
rectifying K+ channels, Kir3. Our results demonstrated that,
in low concentrations, sertraline evokes a planarian seizure-
like activity a fewminutes after exposure.Wehypothesize that
this effectmay be due to a potential inhibition of K+ channels,
such as Kir4.1. The blockade of the astroglial Kir4.1 channels
was related to reduction of both K+ buffering and glutamate
uptake, which could potentially lead to hyperexcitability of
neurons and seizure activity [7, 44–46].
In summary, to our knowledge this is the first study to
investigate the effect of sertraline on behavior and also its
toxicity in planarians.The results demonstrate that sertraline,
over a lowmicromolar range, affects spontaneous locomotory
velocity, evokes episodes of asynchronous paroxysms, and
may be toxic to these animals. Notwithstanding, additional
experiments are still necessary to test our hypothesis that
the effects observed on planarians were due to an action of
sertraline on K+ channels.
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Sauvé, “Distribution of antidepressants and their metabolites in
brook trout exposed to municipal wastewaters before and after
ozone treatment-Evidence of biological effects,” Chemosphere,
vol. 83, no. 4, pp. 564–571, 2011.
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